Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review

[1]  A. Khatami,et al.  Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis , 2023, Future Virology.

[2]  S. Nakahata,et al.  Identification and tracking of HTLV-1–infected T cell clones in virus-associated neurologic disease , 2023, JCI insight.

[3]  H. Katsuya.  Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma , 2023, International Journal of Hematology.

[4]  D. M. de Oliveira,et al.  The Relevance of Telomerase and Telomere-Associated Proteins in B-Acute Lymphoblastic Leukemia , 2023, Genes.

[5]  A. Tavakoli,et al.  Association between Epstein-Bar virus and colorectal cancer: A systematic review and meta-analysis. , 2023, Microbial pathogenesis.

[6]  K. Karube,et al.  A Comprehensive Study of the Immunophenotype and its Clinicopathological Significance in Adult T-cell Leukemia/Lymphoma. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[7]  Jianjun Gao,et al.  Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. , 2022, Drug discoveries & therapeutics.

[8]  A. Utsunomiya,et al.  An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma , 2022, Blood.

[9]  M. Hirosawa,et al.  Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study , 2022, International Journal of Hematology.

[10]  H. Rafatpanah,et al.  HTLV, a multi organ oncovirus. , 2022, Microbial pathogenesis.

[11]  Chun-fung Sin,et al.  The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia , 2021, Frontiers in Oncology.

[12]  G. Barber,et al.  Trial in Progress: A Phase II Trial of Belinostat As Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma (ATLL) , 2021, Blood.

[13]  O. Yoshie.  CCR4 as a Therapeutic Target for Cancer Immunotherapy , 2021, Cancers.

[14]  M. Israel,et al.  Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein , 2021, Scientific Reports.

[15]  R. Danesi,et al.  Clinical pharmacology differences among proteasome inhibitors: implications for their use in clinical practice. , 2021, Pharmacological research.

[16]  L. Cook,et al.  How I treat Adult T-cell leukemia/lymphoma. , 2020, Blood.

[17]  Weijian Guo,et al.  EZH2: a novel target for cancer treatment , 2020, Journal of Hematology & Oncology.

[18]  K. Schmiegelow,et al.  Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. , 2020, Seminars in hematology.

[19]  K. Tsukasaki,et al.  Novel Treatments of Adult T Cell Leukemia Lymphoma , 2020, Frontiers in Microbiology.

[20]  C. Ishikawa,et al.  Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. , 2020, European journal of pharmacology.

[21]  K. Ono,et al.  Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. , 2020, Anti-cancer drugs.

[22]  K. Nakano,et al.  Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas. , 2019, Cell reports.

[23]  F. Prósper,et al.  HDAC Inhibitors in Acute Myeloid Leukemia , 2019, Cancers.

[24]  E. Anguita,et al.  HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[25]  A. Hasegawa,et al.  Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL , 2019, Retrovirology.

[26]  K. Kamachi,et al.  Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma. , 2019, Clinical lymphoma, myeloma & leukemia.

[27]  J. Okamura,et al.  Maintenance of long remission in adult T‐cell leukemia by Tax‐targeted vaccine: A hope for disease‐preventive therapy , 2019, Cancer science.

[28]  I. Sahin,et al.  Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma , 2019, OncoTargets and therapy.

[29]  S. Barta,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib , 2019, Clinical Pharmacokinetics.

[30]  K. Laribi,et al.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. , 2018, The oncologist.

[31]  M. Kasahara,et al.  The immunoproteasome and thymoproteasome: functions, evolution and human disease , 2018, Nature Immunology.

[32]  S. Rezaee,et al.  Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study , 2018, Journal of cellular biochemistry.

[33]  G. Barber,et al.  Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. , 2018, Blood advances.

[34]  K. Tobinai,et al.  A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies , 2018, Advances in Therapy.

[35]  M. Stiborová,et al.  Histone Deacetylase Inhibitors as Anticancer Drugs , 2017, International journal of molecular sciences.

[36]  S. Grelli,et al.  Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α. , 2017, Blood advances.

[37]  H. Earp,et al.  Targeting the TAM Receptors in Leukemia , 2016, Cancers.

[38]  K. Aoyagi,et al.  Ultrasonography and magnetic resonance imaging findings of rheumatoid arthritis-like arthritis in a patient with adult T-cell leukemia , 2016, Modern rheumatology.

[39]  A. Utsunomiya,et al.  Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[41]  K. Nakano,et al.  Polycomb-dependent epigenetic landscape in adult T-cell leukemia. , 2016, Blood.

[42]  M. Ogura,et al.  Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. , 2016, The Lancet. Haematology.

[43]  Andrea K. Thoma-Kress,et al.  Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission , 2016, Viruses.

[44]  K. Morishita,et al.  All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors , 2015, Blood Cancer Journal.

[45]  K. Nakano,et al.  Polycomb-Dependent Epigenetic Landscape in Adult T Cell Leukemia (ATL); Providing Proof of Concept for Targeting EZH1/2 to Selectively Eliminate the HTLV-1 Infected Population , 2015 .

[46]  Y. Hsu,et al.  A rare presentation of adult T-cell leukemia/lymphoma with generalized cutaneous purpuric lesions , 2015 .

[47]  M. Krem,et al.  Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy , 2015, British journal of haematology.

[48]  L. Willems,et al.  Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence , 2015, Viruses.

[49]  K. Akashi,et al.  Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study , 2015, British journal of haematology.

[50]  M. Yoshimitsu,et al.  Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma , 2014 .

[51]  T. Waldmann,et al.  Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. , 2014, Clinical immunology.

[52]  R. Advani,et al.  Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  K. Ishitsuka,et al.  Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. , 2014, The Lancet. Oncology.

[54]  T. Waldmann,et al.  Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model , 2014, Leukemia.

[55]  A. Hasegawa,et al.  HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. , 2014, The Journal of clinical investigation.

[56]  R. Advani,et al.  Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. , 2014, Blood.

[57]  Scott E. Smith,et al.  Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy , 2014, Leukemia & lymphoma.

[58]  Y. Furukawa,et al.  Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia , 2013, Leukemia.

[59]  S. Kinpara,et al.  Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells , 2013, Retrovirology.

[60]  K. Jones,et al.  Pathways of cell-cell transmission of HTLV-1 , 2012, Front. Microbio..

[61]  J. de Lartigue.  Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma. , 2012, Drugs of Today.

[62]  Jianmin Yang,et al.  Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro , 2012, Cancer Chemotherapy and Pharmacology.

[63]  G. Mufti,et al.  Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). , 2012, Leukemia research.

[64]  H. Hoshino.  Cellular Factors Involved in HTLV-1 Entry and Pathogenicit , 2012, Front. Microbio..

[65]  K. McKeage,et al.  Mogamulizumab , 2012, Drugs.

[66]  S. Montoto,et al.  Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Jingjing Xu,et al.  Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity , 2011, Leukemia & lymphoma.

[68]  C. Chen,et al.  Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. , 2011, Leukemia research.

[69]  R. Ueda,et al.  Antibody therapy for Adult T-cell leukemia–lymphoma , 2011, International journal of hematology.

[70]  A. Bazarbachi,et al.  How I treat adult T-cell leukemia/lymphoma. , 2011, Blood.

[71]  T. Sagar,et al.  Adult T-cell leukemia in India: report of two cases and review of literature. , 2011, Journal of cancer research and therapeutics.

[72]  R. Nasr,et al.  Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects? , 2011, Viruses.

[73]  J. Janik,et al.  Disseminated Strongyloides stercoralis Infection in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma , 2011, Acta Haematologica.

[74]  J. Jorgensen,et al.  Results of a Phase 1/2 Study for KW-0761, a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4), In CTCL Patients , 2010 .

[75]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  K. Uozumi,et al.  Treatment for adult T-cell leukemia. , 2010, Cancer chemotherapy and pharmacology.

[77]  K. Ohshima,et al.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  K. Shitara,et al.  Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma , 2010, Clinical Cancer Research.

[79]  N. Maeda,et al.  Susceptibility of human T‐cell leukemia virus type I‐infected cells to humanized anti‐CD30 monoclonal antibodies in vitro and in vivo , 2010, Cancer science.

[80]  H. Kantarjian,et al.  Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Verma,et al.  Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.

[82]  T. Waldmann,et al.  Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. , 2009, Blood.

[83]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. Ruscetti,et al.  Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4+ T cells , 2008, Nature Medicine.

[85]  K. Ishitsuka,et al.  Treatment of adult T‐cell leukemia/lymphoma: past, present, and future , 2008, European journal of haematology.

[86]  H. Koeffler,et al.  Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor κB , 2008 .

[87]  S. Pileri,et al.  Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  S. Plon,et al.  A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study , 2007, Clinical Cancer Research.

[89]  A. Shirdel,et al.  Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran , 2007, Leukemia & lymphoma.

[90]  E. Matutes,et al.  Adult T-cell leukaemia/lymphoma , 2006, Journal of Clinical Pathology.

[91]  S. Plon,et al.  Bortezomib interactions with chemotherapy agents in acute leukemia in vitro , 2006, Cancer Chemotherapy and Pharmacology.

[92]  E. Murphy,et al.  Global epidemiology of HTLV-I infection and associated diseases , 2005, Oncogene.

[93]  H. Sather,et al.  The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: A retrospective study of 295 newly diagnosed patients by the Children's Oncology Group , 2005, Leukemia & lymphoma.

[94]  M. Tomonaga,et al.  Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma , 2005, Leukemia.

[95]  K. Karube,et al.  Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T‐cell leukaemia/lymphoma cells , 2004, British journal of haematology.

[96]  R. Nasr,et al.  Human T-Cell Lymphotropic Virus Type I-Infected Cells Extravasate through the Endothelial Barrier by a Local Angiogenesis-Like Mechanism , 2004, Cancer Research.

[97]  J. Salisbury,et al.  Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. , 2002, Blood.

[98]  C. Tei,et al.  Interferon-α Therapy following Autologous Peripheral Blood Stem Cell Transplantation for Adult T Cell Leukemia/Lymphoma , 2002, Acta Haematologica.

[99]  K. Matsushima,et al.  Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. , 2002, Blood.

[100]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[101]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[102]  A. Stan,et al.  Adult T‐cell lymphoma involving the leptomeninges associated with a spinal cord schwannoma , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.

[103]  P. Grant,et al.  A tale of histone modifications , 2001, Genome Biology.

[104]  C. Tei,et al.  Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma. , 1999, Leukemia & lymphoma.

[105]  M. Tomonaga,et al.  An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[106]  T. Waldmann,et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. , 1995, Blood.

[107]  Y. Ohashi,et al.  Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. , 1994, British Journal of Cancer.

[108]  R. Ohno,et al.  Treatment of adult T‐cell leukemia/lymphoma with MST‐16, a new oral antitumor drug and a derivative of bis(2,6‐dioxopiperazine) , 1993 .

[109]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[110]  D. Shibata,et al.  Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1). , 1989, Annals of internal medicine.

[111]  K. Uozumi,et al.  The prevalence of human T‐cell leukemia virus type I infection in patients with hematologic and nonhematologic diseases in an adult T‐cell leukemia‐endemic area of Japan , 1989, Cancer.

[112]  S. Kamihira,et al.  [Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia]. , 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

[113]  K. Yamaguchi,et al.  STRONGYLOIDES STERCORALIS AS CANDIDATE CO-FACTOR FOR HTLV-I-INDUCED LEUKAEMOGENESIS , 1987, The Lancet.

[114]  Zhang,et al.  Human T-cell lymphotropic virus type I and its oncogenesis , 2017 .

[115]  K. Ohshima,et al.  Six Cases of CD20-Positive Adult T-Cell Leukemia. , 2016, Journal of clinical and experimental hematopathology : JCEH.

[116]  K. Matsushima,et al.  CCR4 and its ligands: from bench to bedside. , 2015, International immunology.

[117]  A. Renand,et al.  Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody , 2008, Leukemia.

[118]  A. Utsunomiya,et al.  [Registration of hematological disorders by the Kyushu Hematology Organization for Treatment (K-HOT) Study Group]. , 2004, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[119]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[120]  A. Bazarbachi,et al.  A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. , 2002, The hematology journal : the official journal of the European Haematology Association.

[121]  D. Catovsky,et al.  Alemtuzumab in T-cell malignancies , 2002, Medical oncology.

[122]  Y. Kodera,et al.  Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[123]  M. Tomonaga,et al.  Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature , 1999, Bone Marrow Transplantation.

[124]  P. Bunn,et al.  T‐Cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T‐cell lymphomas (CTCL) and adult T‐cell leukemia‐lymphomas (ATLL) , 1996, Journal of cellular biochemistry. Supplement.

[125]  T. Waldmann,et al.  The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. , 1993, Blood.